Paige May 1 , Bradley Figgins 2 Show Affiliations »
Abstract
BACKGROUND: Oral anticancer agents are more convenient to use and better tolerated than traditional intravenous therapy but come with significant concerns about patient noncompliance, adverse effects, and high cost. Identifying areas for improvement in the medication use process may help ensure optimal use of these agents. OBJECTIVES: To characterize patient experience with oral anticancer treatment, highlight the areas for improvement in the medication use process, and assess the utility of a pharmacist-led educational program. METHODS: 30 patients who were receiving oral anticancer therapy were administered a brief survey during their visits to an ambulatory Department of Veterans' Affairs oncology clinic where pharmacists are heavily involved in providing initial and follow-up medication use education. Veterans aged 18 years or older were considered for inclusion into the study if they were currently being treated with an oral anticancer medication from a specified list for at least 1 month. Topics addressed included drug information sources, regimen compliance, management of side effects, and cost. The results were results were analyzed using univariate descriptive statistics. RESULTS: Most of the patients were satisfied with their oral treatment, reporting ease of use with minimal side effect occurrence. Oncologists and pharmacists were equally named as sources of drug information. LIMITATIONS: Sample size was small and patients were overwhelmingly male. Response bias may be partially responsible for the observed results for regimen management, side effect occurrence, missed doses, and overall treatment satisfaction. CONCLUSIONS: Oral anticancer therapy represents a significant therapeutic advance for many types of cancer. Pharmacists can serve as vital informational resources to these patients. Further studies examining the role of pharmacist-led educational programs in terms of overall patient outcomes are warranted. ©2016 Frontline Medical Communications.
BACKGROUND: Oral anticancer agents are more convenient to use and better tolerated than traditional intravenous therapy but come with significant concerns about patient noncompliance, adverse effects, and high cost. Identifying areas for improvement in the medication use process may help ensure optimal use of these agents. OBJECTIVES: To characterize patient experience with oral anticancer treatment, highlight the areas for improvement in the medication use process, and assess the utility of a pharmacist-led educational program. METHODS: 30 patients who were receiving oral anticancer therapy were administered a brief survey during their visits to an ambulatory Department of Veterans' Affairs oncology clinic where pharmacists are heavily involved in providing initial and follow-up medication use education. Veterans aged 18 years or older were considered for inclusion into the study if they were currently being treated with an oral anticancer medication from a specified list for at least 1 month. Topics addressed included drug information sources, regimen compliance, management of side effects, and cost. The results were results were analyzed using univariate descriptive statistics. RESULTS: Most of the patients were satisfied with their oral treatment, reporting ease of use with minimal side effect occurrence. Oncologists and pharmacists were equally named as sources of drug information. LIMITATIONS: Sample size was small and patients were overwhelmingly male. Response bias may be partially responsible for the observed results for regimen management, side effect occurrence, missed doses, and overall treatment satisfaction. CONCLUSIONS: Oral anticancer therapy represents a significant therapeutic advance for many types of cancer . Pharmacists can serve as vital informational resources to these patients . Further studies examining the role of pharmacist-led educational programs in terms of overall patient outcomes are warranted. ©2016 Frontline Medical Communications.
Entities: Disease
Species
Keywords:
cancer; oncology pharmacy; oral anticancer therapy; oral chemotherapy
Year: 2016
PMID： 27058868 DOI： 10.12788/jcso.0226
Source DB: PubMed Journal: J Community Support Oncol ISSN： 2330-7749